Chinese Journal of Dermatology ›› 2020, Vol. 53 ›› Issue (7): 573-576.doi: 10.35541/cjd.20191042

• Reviews • Previous Articles     Next Articles

Propranolol for the treatment of infantile hemangioma

Ji cong Jiang1,Jianming Wu1,   

  • Received:2019-10-31 Revised:2020-05-22 Online:2020-07-15 Published:2020-07-06
  • Supported by:
    Wenzhou Basic Research Project

Abstract: 【Abstract】 Propranolol is a non-selective β-adrenoceptor blocker. Various studies have confirmed that it is safe and effective for the treatment of infantile hemangioma. The mechanism of action mainly includes: (1) pericyte-mediated hemodynamic changes and subsequent effects; (2) inhibiting proliferation of hemangioma-derived endothelial cells and stem cells by blocking cell cycle progression, inducing apoptosis of hemangioma-derived endothelial cells and differentiation of hemangioma-derived stem cells into adipocytes; (3) inhibiting the recruitment of endothelial progenitor cells; (4) reducing levels of pro-angiogenic factors, such as vascular endothelial growth factor, matrix metalloproteinase, etc.

Key words: Hemangioma, Infant, Propranolol, Hemodynamics, Endothelial cells, Vascular endothelial growth factors, Matrix metalloproteinases